SCHEMBL24309388

SCHEMBL24309388

Cc1ccccc1-c1nc(NS(=O)(=O)c2cnn(C)c2)nc(Oc2ccc(N3CCN(C)CC3)cc2)c1C#N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ STAT3 P40763 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ RAD52 P43351 1/20 0.37
▸ BRD4 O60885 3/20 0.37
▸ GPR119 Q8TDV5 5/20 0.36
▸ MAP4K1 Q92918 1/20 0.35
▸ PDE2A O00408 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ PTPN1 P18031 1/20 0.34
▸ CSF1R P07333 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ CDK4 P11802 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566880 1.00 JAK2 (0.38) JAK2JAK1TYK2STAT3JAK3
SCHEMBL29567387 0.93 GPR119 (0.41) JAK2RAD52BRD4GPR119CSF1R
SCHEMBL26808857 0.93 GPR119 (0.41) JAK2RAD52BRD4GPR119CSF1R
SCHEMBL29567356 0.88 RAD52 (0.39) JAK2JAK1TYK2STAT3JAK3
SCHEMBL26808918 0.88 RAD52 (0.39) JAK2JAK1TYK2STAT3JAK3
SCHEMBL24310422 0.88 PDE2A (0.40) JAK2JAK3RAD52BRD4MAP4K1
SCHEMBL29567000 0.88 PDE2A (0.40) JAK2JAK3RAD52BRD4MAP4K1
SCHEMBL26808704 0.88 RAD52 (0.39) JAK2JAK1TYK2STAT3JAK3
SCHEMBL24309871 0.88 SCN9A (0.36) JAK2JAK3BRD4GPR119
SCHEMBL29566849 0.88 SCN9A (0.36) JAK2JAK3BRD4GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B JAK2 3498/4885JAK1 3913/4885TYK2 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback